Gallery of new files
Jump to navigation
Jump to search
This special page shows the last uploaded files.
-
Pre-contrast CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg Imam Ali Shah
16:30, 8 May 2024
509 × 428; 34 KB
-
Portal-venous phase CT scan of the abdomen and pelvis in Liver Cirrhosis.png Imam Ali Shah
16:21, 8 May 2024
509 × 428; 170 KB
-
Portal-venous phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg Imam Ali Shah
16:19, 8 May 2024
509 × 428; 30 KB
-
Arterial phase CT scan of the abdomen and pelvis in Cryptogenic Cirrhosis.jpg Imam Ali Shah
16:18, 8 May 2024
509 × 428; 30 KB
-
D2f97c72-bbfb-426e-b742-6e25234ba1ff 2.jpg Alara E. Dagsali
18:44, 22 April 2024
1,280 × 952; 283 KB
-
Ae8d4ea7-c895-403b-a435-56dc4996a3b0.JPG Alara E. Dagsali
18:43, 22 April 2024
1,600 × 1,200; 244 KB
-
Bismuth Subnitrate Package and Label Display Panel.jpg Imam Ali Shah
11:08, 27 March 2024
460 × 500; 181 KB
-
Effects of hepatic impairment and renal impairment on daridorexant PK.png Edzelco
21:07, 31 January 2024
1,230 × 788; 248 KB
-
Effect of daridorexant on the PK of other compounds.png Edzelco
21:07, 31 January 2024
1,250 × 1,086; 543 KB
-
Effect of co-administered compounds on the PK of daridorexant.png Edzelco
21:06, 31 January 2024
1,274 × 1,096; 454 KB
-
Allergic bronchopulmonary aspergillosis.gif Laith Adnan Allaham
13:10, 7 June 2023
407 × 440; 155 KB
-
Table 4 Clinical Data Trial 1 and 2.png Tejasvi Aryaputra
16:09, 20 January 2023
1,328 × 1,226; 254 KB
-
Ibrexafungerp Table 1 Adverse Reactions (Trials 1 and 2).png Tejasvi Aryaputra
16:09, 20 January 2023
1,296 × 516; 95 KB
-
Aducanumab-avwa Table 8 Study 2 Biomarkers.png Tejasvi Aryaputra
21:59, 10 January 2023
1,006 × 990; 196 KB
-
Aducanumab-avwa Table 7 Clinical Results Study 1.png Tejasvi Aryaputra
21:59, 10 January 2023
1,000 × 1,318; 214 KB
-
Aducanumab-avwa Table 6 Study 1 Biomarkers.png Tejasvi Aryaputra
21:59, 10 January 2023
1,350 × 1,318; 231 KB
-
Aducanumab-avwa Table 5 Adverse Reactions.png Tejasvi Aryaputra
21:59, 10 January 2023
1,314 × 1,256; 214 KB
-
Aducanumab-avwa Table 4 ARIA Classification.png Tejasvi Aryaputra
21:59, 10 January 2023
1,326 × 926; 176 KB
-
Aducanumab-avwa Table 3 Dosing Modifciations.png Tejasvi Aryaputra
21:58, 10 January 2023
1,308 × 748; 147 KB
-
Aducanumab-avwa Table 2 Dosing Monitoring.png Tejasvi Aryaputra
21:58, 10 January 2023
1,330 × 718; 136 KB
-
Aducanumab-avwa Figure 4 Clinical Studies.png Tejasvi Aryaputra
21:57, 10 January 2023
1,014 × 944; 305 KB
-
Aducanumab-avwa Figure 3 Clinical Studies.png Tejasvi Aryaputra
21:57, 10 January 2023
1,012 × 990; 219 KB
-
Aducanumab-avwa Figure 2 Clinical Studies.png Tejasvi Aryaputra
21:57, 10 January 2023
1,350 × 1,206; 268 KB
-
Aducanumab-avwa Figure 1 Clinical Studies.png Tejasvi Aryaputra
21:57, 10 January 2023
1,352 × 1,318; 350 KB
-
Aducanumab-avwa Drug Label (3 mL).png Tejasvi Aryaputra
21:56, 10 January 2023
1,362 × 1,100; 583 KB
-
Aducanumab-avwa Drug Label (1.7 mL).png Tejasvi Aryaputra
21:56, 10 January 2023
1,352 × 1,102; 578 KB
-
Rylaze Table 2 Dosage Modifications.png Tejasvi Aryaputra
13:46, 3 January 2023
1,006 × 1,498; 348 KB
-
Upper GI bleeding. Adapted from ACG Clinical Guideline- Upper Gastrointestinal and Ulcer Bleeding.png Jair Basantes de la Calle
13:54, 29 December 2022
1,920 × 1,080; 201 KB
-
Stage A and Stage B recommendations for HF. Adapted from 2022 AHA-ACC-HFSA Guideline for the Management of Heart Failure.png Jair Basantes de la Calle
21:21, 8 December 2022
1,920 × 1,080; 144 KB
-
Recommendation for blood pressure management. Adapted from the 2019 ACC-AHA Guideline on the Primary Prevention of Cardiovascular Disease. .png Jair Basantes de la Calle
19:24, 8 December 2022
1,920 × 1,080; 91 KB
-
Primary Prevention of ASCVD per age group.png Jair Basantes de la Calle
18:28, 8 December 2022
1,920 × 1,080; 318 KB
-
Diagnostic Algorithm for HF and EF-Based Classification.png Jair Basantes de la Calle
12:57, 28 November 2022
1,678 × 1,080; 171 KB
-
Finerenone Table 4 Clinical Studies.png Tejasvi Aryaputra
00:16, 6 September 2022
608 × 1,450; 175 KB
-
Finerenone Table 3 Adverse Reactions.png Tejasvi Aryaputra
00:15, 6 September 2022
1,004 × 656; 85 KB
-
Finerenone Table 2 Dosage Adjustments.png Tejasvi Aryaputra
00:15, 6 September 2022
1,142 × 898; 147 KB
-
Finerenone Figure 2 Clinical Studies.png Tejasvi Aryaputra
00:15, 6 September 2022
1,290 × 1,080; 519 KB
-
Finerenone Figure 1 Clincal Studies.png Tejasvi Aryaputra
00:15, 6 September 2022
1,326 × 1,158; 550 KB
-
Fexinidazole Table 5 Pharmocokinetics.png Tejasvi Aryaputra
02:11, 5 September 2022
640 × 1,514; 262 KB
-
Fexinidazole Table 4 Drug Interactions Pt.4.png Tejasvi Aryaputra
02:10, 5 September 2022
622 × 658; 133 KB
-
Fexinidazole Table 3 Drug Interactions Pt.1.png Tejasvi Aryaputra
02:10, 5 September 2022
612 × 1,028; 209 KB
-
Fexinidazole Table 2 Adverse Reactions Pt.2.png Tejasvi Aryaputra
02:10, 5 September 2022
610 × 546; 78 KB
-
Fexinidazole Table 2 Adverse Reactions.png Tejasvi Aryaputra
02:10, 5 September 2022
622 × 1,308; 188 KB
-
Belumosudil Table 2 Adverse Reactions.png Tejasvi Aryaputra
01:34, 30 August 2022
586 × 1,246; 135 KB
-
Belumosudil Table 2 Adverse Reactions Pt. 2.png Tejasvi Aryaputra
01:32, 30 August 2022
540 × 676; 136 KB